# CDSCO Cancels FatX Import Licence Over Misleading Therapeutic Claims Regulator revokes South Korean cosmetic registration for unauthorized fat-dissolving medical claims. - **Source:** [mint - industry](https://www.livemint.com/rss/industry) - **Published:** 2026-11-02 - **Topic:** [Business](https://brifing.si/c/business) - **Original article:** - **On Brifing:** https://brifing.si/s/99b51687-31f0-45c9-9443-91c68ab3f658 ## Regulatory Action Against FatX The Central Drugs Standard Control Organisation cancelled the import registration for the South Korean cosmetic product FatX. Marketed by Delhi-based Tekno Midas Aesthetics, the product faced scrutiny for making therapeutic claims regarding fat cell dissolution. The regulator determined these assertions violated the Drugs and Cosmetics Act, 1940, by misrepresenting a cosmetic as a drug. ## Defining Cosmetics Versus Drugs Under the 1940 Act, cosmetics are strictly limited to products applied for cleansing, beautifying, or altering visual appearance. The CDSCO ruled that claiming to dissolve fat cells implies physiological changes, which necessitates the stricter regulatory approval process required for drugs. Marketing such products as simple cosmetics constitutes a significant violation of established safety standards. ## Evidence of Marketing Mismatches A detailed scrutiny of the importer’s website revealed major discrepancies between legally cleared product labels and public marketing materials. While the approved registration was for cosmetic use, the website promoted the solution as a medical treatment. This mismatch between authorized documentation and active consumer-facing claims triggered the formal investigation by the licensing authority. ## Failed Defense and Licence Cancellation Following a show-cause notice issued on 10 August 2026, the firm submitted an unsatisfactory response on 1 September 2026. Instead of providing a valid defense, the company requested a voluntary surrender of its licence. Drugs Controller General Rajeev Singh Raghuvanshi rejected this plea and invoked Rule 16 to cancel the registration immediately. ## Broader Industry Surveillance Trends This cancellation reflects the CDSCO’s heightened surveillance over imported aesthetic solutions and injectables. The regulator is actively targeting firms that bypass statutory clearances by misbranding products. This specific enforcement action serves as a warning to other importers who exploit the simpler cosmetic regulatory pathway to market products with unverified therapeutic medical benefits. ## Precedent in Market Enforcement The crackdown extends beyond this single case, as the regulator previously cancelled three import registrations for Skintl Enterprises in September 2026. Those violations involved misbranding, unauthorized storage, and labelling issues. These consecutive actions demonstrate a systematic effort by Indian authorities to sanitize the domestic market of misleading aesthetic and pharmaceutical product claims. ## Expert Perspective on Compliance Dr. Saurabh Arora of Auriga Research notes that exploiting the cosmetic regulatory pathway is a common industry practice. He emphasizes that cosmetics must act only on the surface to remain compliant. Claims involving cellular destruction inherently shift a product into the drug category, requiring rigorous clinical validation that these cosmetic importers currently lack. ## Impact of Regulatory Rigor The immediate cancellation of the FatX permit, originally valid until July 2027, underscores the government's commitment to consumer safety. By enforcing strict adherence to the Drugs and Cosmetics Rules, 2020, the CDSCO aims to prevent unsafe products from reaching the public. Future market entrants must now ensure absolute alignment between their labels and marketing. ## Sources covering this story - https://www.livemint.com/industry/cdsco-cancels-import-licence-of-korean-cosmetic-fatx-over-fat-dissolving-claim-11793514855384.html — --- _Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._